SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.
SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.
复制标题
SGLT2 抑制剂作为糖尿病肾病的治疗选择。
DOI：
10.3390/ijms18051083
复制
发表时间：
2017-05-18
影响因子：
5.6
通讯作者：
Utsunomiya K
中科院分区：
文献类型：
--
作者：
Kawanami D;Matoba K;Takeda Y;Nagai Y;Akamine T;Yokota T;Sango K;Utsunomiya K
糖尿病肾病（DN）是全球终末期肾病（ESRD）的主要原因。血糖和血压控制是重要的，但不足以减少DN的发生和进展。钠-葡萄糖协同转运蛋白（SGLT）2抑制剂是一类新的降糖药物，具有降糖依赖性和非依赖性的肾脏保护作用。实验研究表明，SGLT 2抑制剂可减轻1型糖尿病（T1 D）和2型糖尿病（T2 D）动物模型中的DN，表明其潜在的肾脏保护作用超出了降糖作用。在随机对照试验（RCT）中，SGLT 2抑制剂的肾保护作用已在心血管高风险T2 D患者中得到证实。SGLT 2抑制剂的这些有利作用可以通过几种潜在机制来解释，包括肾小球超滤、炎症和氧化应激的减弱。在这篇综述文章中，我们通过将实验结果与现有临床数据相结合来讨论SGLT 2抑制剂的肾保护作用。
Diabetic nephropathy (DN) is a major cause of end-stage renal disease (ESRD) worldwide. Glycemic and blood pressure (BP) control are important but not sufficient to attenuate the incidence and progression of DN. Sodium–glucose cotransporter (SGLT) 2 inhibitors are a new class of glucose-lowering agent suggested to exert renoprotective effects in glucose lowering-dependent and independent fashions. Experimental studies have shown that SGLT2 inhibitors attenuate DN in animal models of both type 1 diabetes (T1D) and type 2 diabetes (T2D), indicating a potential renoprotective effect beyond glucose reduction. Renoprotection by SGLT2 inhibitors has been demonstrated in T2D patients with a high cardiovascular risk in randomized controlled trials (RCTs). These favorable effects of SGLT2 inhibitors are explained by several potential mechanisms, including the attenuation of glomerular hyperfiltration, inflammation and oxidative stress. In this review article, we discuss the renoprotective effects of SGLT2 inhibitors by integrating experimental findings with the available clinical data.